Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials

<div>Safety outcomes of guselkumab in the treatment of plaque psoriasis versus placebo or adalimumab. AEs: adverse events; SAEs: serious adverse events.</div>

Journal of Immunology Research

fig5

Figure 5

Figure 5: Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials 

Figure 5 | Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials 